{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "APTA.L",
  "generated_at": "2026-01-22T22:04:49.055543Z",
  "top_card": {
    "ticker": "APTA.L",
    "company_name": "Aptamer Group PLC",
    "sector": "Healthcare",
    "market_cap_gbp": 24272804,
    "days_active": 524,
    "apex_score_100": 55,
    "confidence_score_100": 40,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 55/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Aptamer Group PLC",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 24272804,
      "current_close_price": 0.9
    },
    "basics": {
      "ticker": "APTA.L",
      "current_price": 0.9,
      "ath": 157.0,
      "atl": 0.2,
      "ath_date": "2022-01-05",
      "atl_date": "2024-07-24",
      "week_52_high": 1.57,
      "week_52_low": 0.231,
      "week_52_high_date": "2025-09-02",
      "week_52_low_date": "2025-04-23",
      "drawdown_from_ath_pct": 99.43,
      "data_start": "2021-12-22",
      "data_end": "2026-01-22",
      "total_bars": 1029
    },
    "latest_signal": {
      "date": "2024-08-16",
      "scan_date": "2026-01-14",
      "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
      "signal_color": "PURPLE",
      "price": 0.23,
      "drawdown_pct": 85.53,
      "ai_score": 9.0,
      "rsi": 38.9,
      "cycle_position": 0.0462,
      "holding_period_days": 524,
      "current_pnl_pct": 291.3,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -23.85,
      "Rally_Count": 2,
      "days_since_last_high": 14,
      "last_high_date": "2025-12-31",
      "lock_in_reached": true,
      "lock_in_date": "2025-09-01",
      "best_rally_pct": 465.22
    },
    "best_historical_signal": {
      "signal_date": "2024-08-16",
      "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
      "signal_color": "PURPLE",
      "entry_price": 0.23,
      "peak_price": 1.57,
      "peak_date": "2025-09-02",
      "rally_pct": 582.61,
      "days_to_peak": 382,
      "ai_score": 9.0
    },
    "all_historical_signals": [
      {
        "signal_id": "APTA.L_2023-04-11",
        "signal_date": "2023-04-11",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 25.5,
        "current_price": 0.99,
        "current_return_pct": -96.12,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-04-12",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 1009,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-04-12",
        "signal_date": "2023-04-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 25.5,
        "current_price": 0.99,
        "current_return_pct": -96.12,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-04-13",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 1008,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-05-05",
        "signal_date": "2023-05-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 13.0,
        "current_price": 0.99,
        "current_return_pct": -92.38,
        "best_rally_pct": 34.62,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.34,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 985,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-05-09",
        "signal_date": "2023-05-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 13.0,
        "current_price": 0.99,
        "current_return_pct": -92.38,
        "best_rally_pct": 34.62,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.34,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 981,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-05-10",
        "signal_date": "2023-05-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 13.0,
        "current_price": 0.99,
        "current_return_pct": -92.38,
        "best_rally_pct": 34.62,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.34,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 980,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-06-12",
        "signal_date": "2023-06-12",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 9.0,
        "current_price": 0.99,
        "current_return_pct": -89.0,
        "best_rally_pct": 94.44,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.34,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 947,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-07-04",
        "signal_date": "2023-07-04",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 4.5,
        "current_price": 0.99,
        "current_return_pct": -78.0,
        "best_rally_pct": 11.11,
        "best_rally_date": "2023-07-07",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -80.2,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 925,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-07-07",
        "signal_date": "2023-07-07",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.0,
        "current_price": 0.99,
        "current_return_pct": -80.2,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-07-10",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 922,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-07-17",
        "signal_date": "2023-07-17",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 4.25,
        "current_price": 0.99,
        "current_return_pct": -76.71,
        "best_rally_pct": 11.76,
        "best_rally_date": "2023-07-26",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -79.16,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 912,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-07-31",
        "signal_date": "2023-07-31",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 2.0,
        "current_price": 0.99,
        "current_return_pct": -50.5,
        "best_rally_pct": 23.0,
        "best_rally_date": "2023-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.76,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 898,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-01",
        "signal_date": "2023-08-01",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 2.25,
        "current_price": 0.99,
        "current_return_pct": -56.0,
        "best_rally_pct": 9.33,
        "best_rally_date": "2023-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -59.76,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 897,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-02",
        "signal_date": "2023-08-02",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 2.0,
        "current_price": 0.99,
        "current_return_pct": -50.5,
        "best_rally_pct": 23.0,
        "best_rally_date": "2023-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.76,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 896,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-03",
        "signal_date": "2023-08-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 2.25,
        "current_price": 0.99,
        "current_return_pct": -56.0,
        "best_rally_pct": 9.33,
        "best_rally_date": "2023-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -59.76,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 895,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-17",
        "signal_date": "2023-08-17",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 1.3,
        "current_price": 0.99,
        "current_return_pct": -23.85,
        "best_rally_pct": 11.54,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -31.72,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 881,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-18",
        "signal_date": "2023-08-18",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.2,
        "current_price": 0.99,
        "current_return_pct": -17.5,
        "best_rally_pct": 20.83,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -31.72,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 880,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-21",
        "signal_date": "2023-08-21",
        "signal_type": "ENHANCED ULTRA CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.225,
        "current_price": 0.99,
        "current_return_pct": -19.18,
        "best_rally_pct": 18.37,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -31.72,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 877,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-23",
        "signal_date": "2023-08-23",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.2,
        "current_price": 0.99,
        "current_return_pct": -17.5,
        "best_rally_pct": 20.83,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -31.72,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 875,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-24",
        "signal_date": "2023-08-24",
        "signal_type": "ENHANCED ULTRA CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.225,
        "current_price": 0.99,
        "current_return_pct": -19.18,
        "best_rally_pct": 18.37,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -31.72,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 874,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-25",
        "signal_date": "2023-08-25",
        "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.25,
        "current_price": 0.99,
        "current_return_pct": -20.8,
        "best_rally_pct": 16.0,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -31.72,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 873,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-30",
        "signal_date": "2023-08-30",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.175,
        "current_price": 0.99,
        "current_return_pct": -15.74,
        "best_rally_pct": 23.4,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -31.72,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 868,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-09-04",
        "signal_date": "2023-09-04",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.125,
        "current_price": 0.99,
        "current_return_pct": -12.0,
        "best_rally_pct": 28.89,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -31.72,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 863,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-01",
        "signal_date": "2024-02-01",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.9,
        "current_price": 0.99,
        "current_return_pct": 10.0,
        "best_rally_pct": 44.44,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 713,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-05",
        "signal_date": "2024-02-05",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.725,
        "current_price": 0.99,
        "current_return_pct": 36.55,
        "best_rally_pct": 79.31,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 709,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-06",
        "signal_date": "2024-02-06",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.725,
        "current_price": 0.99,
        "current_return_pct": 36.55,
        "best_rally_pct": 79.31,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 708,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-07",
        "signal_date": "2024-02-07",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.725,
        "current_price": 0.99,
        "current_return_pct": 36.55,
        "best_rally_pct": 79.31,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 707,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-21",
        "signal_date": "2024-02-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.625,
        "current_price": 0.99,
        "current_return_pct": 58.4,
        "best_rally_pct": 108.0,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 693,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-03-21",
        "signal_date": "2024-03-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.575,
        "current_price": 0.99,
        "current_return_pct": 72.17,
        "best_rally_pct": 126.09,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 664,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-03-28",
        "signal_date": "2024-03-28",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.575,
        "current_price": 0.99,
        "current_return_pct": 72.17,
        "best_rally_pct": 126.09,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 657,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-04-04",
        "signal_date": "2024-04-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.5,
        "current_price": 0.99,
        "current_return_pct": 98.0,
        "best_rally_pct": 160.0,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 650,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-07-24",
        "signal_date": "2024-07-24",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.25,
        "current_price": 0.99,
        "current_return_pct": 296.0,
        "best_rally_pct": 420.0,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 539,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-07-25",
        "signal_date": "2024-07-25",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.3,
        "current_price": 0.99,
        "current_return_pct": 230.0,
        "best_rally_pct": 333.33,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 538,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-07-26",
        "signal_date": "2024-07-26",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.26,
        "current_price": 0.99,
        "current_return_pct": 280.77,
        "best_rally_pct": 400.0,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 537,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-08-14",
        "signal_date": "2024-08-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.24,
        "current_price": 0.99,
        "current_return_pct": 312.5,
        "best_rally_pct": 441.67,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 518,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-08-16",
        "signal_date": "2024-08-16",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 0.23,
        "current_price": 0.99,
        "current_return_pct": 330.43,
        "best_rally_pct": 465.22,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -23.85,
        "days_since_last_high": 14,
        "lock_in_reached": true,
        "age_days": 516,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 34,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 147.74,
      "median_rally_pct": 94.44,
      "best_rally_pct": 582.61,
      "worst_rally_pct": 9.33
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-22 20:06:51 UTC",
    "volatility": {
      "atr_normalized": 6.11,
      "stddev_20d": 0.6931
    },
    "trends": {
      "intelligence_signal": "DOWNTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 55/100 indicates strong opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 2 rallies, 465% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "APTA.L",
      "latest": [
        {
          "title": "Trading update - Media comment and speculation",
          "announcement_date": "7th Jan 2026",
          "release_time": "4:04 pm",
          "source": "RNS",
          "content": "7 Jan 2026 16:04\nRNS Number : 0517O\nAptamer Group PLC\n07 January 2026\n7 January 2026\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nTrading update - Media comment and speculation\nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, provides an update regarding media comment and speculation following the trading update released by the Company earlier today. The Company confirms that the Group's cash position provides a runway through to June 2027 in line with the previous statements (see RNS 14 October 2025, \"Full year results for the twelve months ended 30 June 2025\").\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a\nleading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group\ndevelops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTSSDFMWEMSESF",
          "rns_number": "RNS Number : 0517O"
        },
        {
          "title": "Half Year Trading Update",
          "announcement_date": "7th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "7 Jan 2026 07:00\nRNS Number : 8991N\nAptamer Group PLC\n07 January 2026\n7 January 2026\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nHalf Year Trading Update\nRevenue up 27% to \u00a30.83 million with an FY26 fee-for-service order book of over \u00a32.0 million\nStrong sales pipeline of \u00a33.1 million\nMultiple licensing opportunities in advanced stages already generating revenue\nContinued delivery on technical and commercial objectives to support financial strategy\nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce a trading update for the six months ending\u00a031 December 2025\u00a0(H1 26).\nFinancial performance\nAptamer's unaudited revenue for H1 26 is \u00a30.83 million, representing a substantial 27% increase from the same period last year (H1 25: \u00a30.65 million), and gives the Board confidence that full year revenue will materially exceed the prior year.\nThe Group has an FY26 fee-for-service order book of over \u00a32.0 million in new contracts. In line with previous years, approximately 70% of this revenue is expected to be recognised during the financial year. In addition, the Group maintains a strong sales pipeline of \u00a33.1 million as of today. The ongoing conversion and replenishment of this pipeline demonstrates the Group's ability to consistently convert opportunities into contracted revenue.\nStrategic progress towards a recurring revenue model\nThe Group is successfully executing its stated strategy of building a sustainable, high-margin business model through fee-for-service revenue and licensing partnerships. The period has seen significant acceleration in converting its proprietary technology and intellectual property (IP) into commercial licensing opportunities and executed agreements, marking a transition from development to commercialisation.\nLicensing Agreements\n\u00b7\nTwo non-exclusive licensing contracts were signed in December 2025 with Twist Bioscience and Alphazyme, part of Maravai LifeSciences, delivering immediate upfront payments with ongoing revenues through milestone payments, royalties and manufacturing income. The first commercial sales are anticipated in H2 26.\n\u00b7\nA third partner, a global manufacturer of a specific enzyme, is currently evaluating the hot-start PCR Optimer\u00ae under a Material Transfer Agreement for potential non-exclusive licensing and has extended its current contract to continue testing following initial results.\n\u00b7\nGlobal health partnership advancing, with negotiations in the final stages for licensing of a vitamin B9 Optimer\u00ae to support worldwide diagnostics, representing entry into a high-volume, socially impactful market.\nBlue-Chip Partnership Portfolio Expanding\nThe Group continues to deepen relationships with world-leading commercial partners, positioning multiple assets for near-term licensing conversion:\n\u00b7\nUnilever programmes advancing through development stages: Stability assessment work on the first deodorant programme was successfully completed and delivered, supporting the current on-skin testing phase. The second programme targeting an additional pathway to prevent odour generation is progressing well with positive internal results and imminent delivery to Unilever for evaluation.\n\u00b7\nAlphazyme partnership demonstrates repeatable licensing:\no\nInitial project successfully completed and converted into a non-exclusive licensing agreement, with first commercial sales anticipated in H2 26.\no\nSecond discovery project with Alphazyme already completed, with high-performance binders selected by the customer, which provides strong potential for a second licensing agreement within the current financial year.\n\u00b7\nTop 3 pharmaceutical partner secured for radioligand development: Major contract win that marks Aptamer's successful entry into rapidly growing radioligand market with significant addressable market opportunity. This represents a pivotal strategic milestone for the Group, validated by the recent appointment of a radioligand specialist to Aptamer's Scientific Advisory Board to support the Group's capabilities and ambitions in this high-value sector.\n\u00b7\nSignificant repeat business from top-tier pharmaceutical partners: The period showed strong validation with \u00a3719,000 in new contracts secured from a single top 5 pharmaceutical partner of which \u00a3314,000 has been recognised as revenue to date. This new business represents over \u00a31 million in total contract value with this partner across the past two financial years, alongside an additional repeat contract with a top 10 pharmaceutical company, underscoring the commercial value and performance of the Optimer\u00ae platform.\n\u00b7\nOptimer\u00ae immunohistochemistry (IHC) reagents have been successfully developed for an established global life sciences and diagnostics conglomerate, with the potential to be integrated into assay kits this year and agreed royalties of 2% on net sales of all products.\nProprietary Therapeutic Pipeline De-Risking\n\u00b7\nInternal testing of a fibrotic liver delivery vehicle has shown excellent preclinical characteristics of being non-toxic, stable, and non-immunogenic, which significantly de-risks its therapeutic potential.\n\u00b7\nCommencement of animal studies is anticipated this financial year to demonstrate targeting performance and supporting active partnering discussions for this potentially high-value therapeutic asset.\nDelivering on strategy\nDuring the period, the Group has made substantial progress delivering against its stated strategic objectives:\n\u00b7\nRevenue growth delivered: 27% increase demonstrates continued commercial traction;\n\u00b7\nMultiple licensing agreements signed: Validating the model to retain IP and start delivering passive income through licensing;\n\u00b7\nPartnership portfolio strengthened: Expanded relationships with global leaders across pharmaceutical, diagnostics, and consumer goods sectors;\n\u00b7\nIP portfolio enhanced: Growing library of proprietary assets creating multiple licensing opportunities;\n\u00b7\nFinancial trajectory improving: Combination of growing fee-for-service revenue with emerging high-margin licensing income driving operational leverage.\nAptamer has established clear momentum in enhancing its business model with sustainable, recurring revenue streams. With multiple licensing agreements now signed and generating income post period, a robust pipeline of partnered licensing opportunities showing progression, and continued strong demand from blue-chip partners, the Group is well-positioned to continue this positive trajectory.\nDr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:\n\"This has been an exceptional period for Aptamer as we deliver on our strategic commitments to shareholders. The 27% revenue growth, combined with the signing of multiple licensing agreements that are now generating immediate income, demonstrates the commercial validation of the Group's platform and our ability to execute against our stated objectives.\nWhile this H1 update naturally focuses on near-term revenue and financial metrics, it is important to remember the broader progress we are making across the business. Our opportunity for major growth inflection is within our growing licensing portfolio, including opportunities such as the radioligand drug development project with the top 3 pharma partner.\nAll combined, this demonstrates not only the commercial use of our technology but also our deepening partnerships with big pharma leaders, global consumer goods companies and major health organisations. These relationships are not just driving current cash flows but are building a foundation for long-term shareholder value. Each fee-for-service project delivers immediate revenue while simultaneously creating proprietary intellectual property and opportunities that unlock potential future licensing revenue and create an upward cycle of growth.\nThe quality of our partnerships and growing repeat business with top 10 pharma partners builds a valuable dual revenue approach, which allows us to take advantage of our operational leverage and positioning as a key leader in the space. Each positive addition puts us one step closer to achieving our strategic and financial objectives. Now, with multiple licensing opportunities in advanced stages, a robust sales pipeline of over \u00a33 million, and continued strong demand from industry leaders, we are confident in our ability to continue this positive trajectory and create substantial shareholder value.\"\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a\nleading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group\ndevelops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTUNRURNKUARUR",
          "rns_number": "RNS Number : 8991N"
        },
        {
          "title": "Aptamer signs licensing agreement with Alphazyme",
          "announcement_date": "23rd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "23 Dec 2025 07:00\nRNS Number : 6368M\nAptamer Group PLC\n23 December 2025\n23 December 2025\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nAptamer signs licensing agreement with Alphazyme\nNon-exclusive OEM license for enzyme-modulating\nOptimer\nRoyalty payments on product sales plus milestone and manufacturing revenues\nSecond licensing deal demonstrates commercial validation of\nOptimer\u00ae\nplatform\nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences (\nNASDAQ: MRVI)\ncompany and global provider of specialty enzymes used in the life sciences sector, have entered into a licensing agreement for a developed Optimer\u00ae for use in hot-start PCR applications.\nThis binder acts as a precise molecular control mechanism in hot-start DNA amplification, a widely used laboratory technique in which the key enzyme is kept inactive at lower temperatures and only switches on when heated. This prevents unwanted DNA copying early in the process, leading to much more accurate and reliable results in applications such as genetic testing, diagnostic assays, and library preparation for next-generation sequencing (NGS), the high-throughput technology that allows rapid and cost-effective analysis of millions of DNA fragments in parallel.\nAgreement advances product portfolio for both companies\nUnder the terms of the agreement, Aptamer grants Alphazyme a non-exclusive licence for use of an enzyme-modulating Optimer\u00ae in hot-start PCR and next-generation sequencing (NGS) applications within Alphazyme's own products and services. The agreement provides worldwide rights to Alphazyme and includes royalty payments on sales of products, milestone payments, and a supply agreement for the manufacturing of the Optimer\u00ae. Aptamer will manufacture the Optimer\u00ae for Alphazyme, providing quality assurance and supply chain security whilst generating additional manufacturing revenue.\nRapid progression from development to licence\nAptamer and Alphazyme originally signed a development agreement for the hot-start PCR Optimer\u00ae in June 2024, with delivery of the final product in December 2024. Alphazyme demonstrated successful performance in its laboratory tests, showing temperature-sensitive control of the enzyme's exonuclease and polymerase activities. The Optimer\u00ae achieves what typically requires two antibodies, offering performance enhancement and cost advantages.\nFollowing this success, a second Optimer\u00ae development programme for enzyme modulation has been initiated with Alphazyme to broaden the customer's product portfolio. This project has recently completed the development phase, with candidate molecules having been delivered to Alphazyme for internal testing with positive results in the customer's hands.\nDr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:\n\"\nWe are delighted to announce the signing of this licensing agreement with Alphazyme. This second\nenzyme modulation\nlicensing agreement validates both the technical performance and commercial appeal of Optimer\u00ae technology in the molecular biology market. One of the standout features is the ability of our product to replace two antibodies with a single product, offering significant performance and manufacturing advantages, which will drive further\nlicensing opportunities on successful technical validation of the second project.\n\"\nWe look forward to building on the relationship with Alphazyme through our ongoing development programmes, which will provide the opportunity for further licensing of our Optimer\u00ae technology.\n\"\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRQXLBLELLLFBB",
          "rns_number": "RNS Number : 6368M"
        },
        {
          "title": "Licensing agreement with Twist Bioscience",
          "announcement_date": "16th Dec 2025",
          "release_time": "10:34 am",
          "source": "RNS",
          "content": "16 Dec 2025 10:34\nRNS Number : 7785L\nAptamer Group PLC\n16 December 2025\n16 December 2025\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nAptamer signs licensing agreement with Twist Bioscience\nNon-exclusive license for Optimer\u00ae binder targeting the next-generation sequencing market\nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce a first licensing agreement with Twist Bioscience, a leading synthetic biology and genomics company.\nUnder the terms of the agreement, Aptamer has granted Twist Bioscience a non-exclusive license for use of a proprietary enzyme-modulating Optimer\u00ae binder in both existing and future hot-start PCR, a highly precise version of the standard DNA copying process, and next-generation sequencing (NGS) products.\nNGS represents a rapidly expanding market, driven by increasing applications across healthcare, agriculture, and research. The NGS market is expected to reach US$23.6bn by 2029, with a CAGR of 13.2%\n1\n. Twist Bioscience is a market leader in synthetic DNA and has established a strong position in NGS library preparation, making it an ideal partner for commercialising Aptamer's binder technology in this high-growth sector.\nThis\nOptimer\u00ae\ndevelopment project, completed in partnership with Twist Bioscience, was signed, delivered, and validated. The resulting enzyme-modulating Optimers provide precise, temperature-dependent control for both research and assays. In hot-start PCR applications, the\nOptimer\u00ae\nbinder demonstrates robust performance, eliminating the need for two separate antibody reagents typically required in alternative methods.\nUnder the agreement, Aptamer will supply the\nOptimer\u00ae\nbinder to Twist Bioscience. The partnership allows Aptamer to maximise value from its intellectual property and directly participate in the market success of products incorporating its\nOptimer\u00ae\ntechnology. Aptamer establishes long-term partnerships built on shared incentives and collaborative growth, ensuring sustained value creation from its innovative biotechnology assets.\nDr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:\n\"This licensing agreement with Twist Bioscience represents a significant step forward in Aptamer's strategy to build a licensing-led revenue model. It validates the commercial potential of our binders in the NGS market and provides a structure that combines upfront payments with ongoing royalties, demonstrating how our platform can deliver sustainable and recurring income streams.\n\"By directly supplying Twist Bioscience with\nOptimer\u00ae\nreagents, we can ensure the high quality and performance standards while embedding our technology into their NGS portfolio. Twist Bioscience is recognised globally as a leader in synthetic DNA and sequencing tools, and its scale and established customer base provide an excellent route to market for our binders. With the NGS sector showing continued growth, this partnership positions Aptamer to participate in that growth alongside a proven market leader. We look forward to supporting Twist Bioscience in expanding its sequencing solutions and to building further licensing opportunities across our technology base.\"\n1.\nhttps://www.marketsandmarkets.com/Market-Reports/next-generation-sequencing-ngs-technologies-market-546.html\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a\nleading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group\ndevelops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nAbout Twist Bioscience\nhttps://www.twistbioscience.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRGPGPWPUPAGUQ",
          "rns_number": "RNS Number : 7785L"
        },
        {
          "title": "Results of 2025 Annual General Meeting",
          "announcement_date": "27th Nov 2025",
          "release_time": "1:01 pm",
          "source": "RNS",
          "content": "27 Nov 2025 13:01\nRNS Number : 3251J\nAptamer Group PLC\n27 November 2025\n27 November 2025\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nResults of 2025 Annual General Meeting\nAptamer Group plc\n(AIM: APTA), the\nleading developer of next-generation synthetic binders delivering innovation to the life science industry\n,\ntoday announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting (AGM) held earlier today at\u00a011:00 am\u00a0at the offices of\u00a0Aptamer Group, Windmill House,\u00a0Innovation Way, York, YO23 1LR, all Resolutions were duly passed.\nFurther details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 3 November 2025, and the full poll results will be made available on the Aptamer website later today.\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a\nleading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group\ndevelops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGLDLFLEFLEFBK",
          "rns_number": "RNS Number : 3251J"
        }
      ],
      "themes": [
        "drilling",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 338,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "DOWNTREND"
    },
    "volatility": {
      "atr_normalized": 6.11,
      "stddev_20d": 0.6931
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2025-09-01"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "INDUSTRIALS",
      "name": "Industrials",
      "icon": "\ud83c\udfed",
      "color": "#64748b",
      "crash_patterns": [
        "Order book decline or cancellations",
        "Margin compression (input costs)",
        "Cyclical demand weakness",
        "Project delays or overruns",
        "Working capital strain"
      ],
      "recovery_paths": [
        "Order book growth or new contracts",
        "Margin recovery (efficiency gains)",
        "Cyclical upturn (capex recovery)",
        "M&A consolidation",
        "Product innovation or new markets"
      ],
      "active_patterns": [],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Order book value (forward revenue)",
        "Book-to-bill ratio",
        "Operating margin trends",
        "Working capital efficiency",
        "Capex cycles (customer industries)"
      ]
    },
    "panic_analysis": {
      "panic_score": 70,
      "signal": "HIGH_PANIC",
      "interpretation": "\ud83d\udfe0 Fear dominant - watch for reversal signs",
      "breakdown": {
        "price_destruction": 40,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": true,
      "opportunity_reason": "\u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 40/40 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 465% proven capacity"
      ],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "HIGH_PANIC",
        "icon": "\ud83d\udfe0",
        "text": "Fear 70/100",
        "color": "#f59e0b"
      },
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 55",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Trading update - Media comment and speculation",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Half Year Trading Update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Aptamer signs licensing agreement with Alphazyme",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Licensing agreement with Twist Bioscience",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Results of 2025 Annual General Meeting",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "BUY",
      "reason": "\ud83c\udfaf CrashHunter Signal: \u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "70/100",
          "pass": true,
          "icon": "\ud83d\udd34"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "55/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "0 active",
          "pass": true,
          "icon": "\ud83c\udfed"
        }
      ],
      "pass_rate": "5/5"
    },
    "contrarian_panic": {
      "total_score": 48,
      "band": "\ud83d\udfe1 MODERATE COMPRESSION (Top 30% - GOOD SETUP)",
      "components": {
        "compression": {
          "score": 17,
          "max": 40,
          "signals_30d": 5,
          "signals_60d": 5,
          "signals_90d": 5,
          "signals_per_week": 0.38,
          "total_signals": 34,
          "rsi_extreme_count": 3,
          "rsi_ultra_count": 2,
          "escalation_count": 1,
          "density_score": 3,
          "rsi_score": 7,
          "escalation_score": 4,
          "description": "0.4 signals/week | 3 RSI<20 | 1 escalations | \ud83d\udcca MODERATE COMPRESSION"
        },
        "intensification": {
          "score": 8,
          "max": 20,
          "recent_types": [
            "EXTREME CRASH BOTTOM",
            "DEEP CRASH BOTTOM",
            "ENHANCED CRASH CRASH-ACCUM COMBO"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 5,
          "pattern": "AT EXTREME LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.15,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 10,
          "max": 15,
          "best_historical_rally": 465.2,
          "avg_rally": 97.3,
          "signal_count": 34,
          "description": "SOLID MOVER - Historical 3x+ (465%)"
        },
        "accumulation": {
          "score": 8,
          "max": 10,
          "has_accumulation": true,
          "bars_since_accum": 2,
          "description": "Accum 2 bars ago"
        }
      },
      "ticker": "APTA.L",
      "signal_date": "2024-08-16",
      "total_signals_history": 34
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +17 (Drawdown_Pct=85.5%)",
      "Volume confirmation: +10 (Relative_Volume=2.1)",
      "Pattern reliability: +5 (Rally_Count=2.0)",
      "Upside history: +12 (best_rally_pct=465%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 17,
      "drawdown_pct": 85.53,
      "reason": "Drawdown of 85.5% gives 17/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.15,
      "reason": "Relative volume 2.15x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 2.0,
      "reason": "2.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 12,
      "best_rally_pct": 465.22,
      "reason": "Best rally of 465% gives 12/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=330.4%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2024-08-16"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.71,
    "current_run_pct": 330.43,
    "avg_historical_run_pct": 465.22
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 55/100 APEX score. Historical data shows 2 rallies averaging 465% upside. Current position: +330.4%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}